Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellular Dynamics Launches iCell Cardiomyocytes
Cellular Dynamics (CDI) has launched iCell Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry. These human heart cells are designed to aid drug
Cellular Dynamics (CDI) has launched iCell Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry. These human heart cells are designed to aid drug
Pfizer has reported that the patients treated with Toviaz (fesoterodine fumarate) 8mg extended release tablets had greater and statistically reductions in urge urinary incontinence episodes at week 12
BioSpecifics Technologies has reported top-line efficacy and safety results from a Phase 2b clinical trial of Xiaflex for the treatment of peyronie’s disease. The Phase 2b study, conducted
Array BioPharma (Array) and Amgen have entered into an agreement. The deal grants Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested
Gilead Sciences (Gilead) has reported that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan did not achieve its co-primary efficacy endpoints of change from baseline to week
EpiCept has provided an update on new clinical developments and other initiatives related to Ceplene (histamine dihydrochloride) therapy, approved in the EU, for the remission maintenance and prevention
Elan and Transition Therapeutics have notified clinical investigators of modifications to the Phase II study AD201, and open label extension study AD251, for ELND005, a compound being developed
The Takeda Oncology Company and the parent company, Takeda Pharmaceutical have jointly announced that Seattle Genetics and Millennium have entered into an agreement to develop and commercialise Brentuximab
Addex Pharmaceuticals has decided to end prematurely the migraine prevention study 206. Reportedly, the routine safety monitoring of blinded data in study 206, has revealed an incidence of
Ablynx has initiated a double-blind, randomised, placebo-controlled Phase I study with ALX-0141, a nanobody targeting Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), in healthy postmenopausal women.